



Biomarker research to improve clinical outcomes in peritoneal dialysis-- Consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) Network

Journal:	<i>Kidney International</i>
Manuscript ID	KI-11-16-1766.R1
Article Type:	REVIEW
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Aufricht, Christoph; Medical University of Vienna, Department of Pediatrics and Adolescent Medicine Beelen, Robert; VU University Medical Center, mol cell biopl & immunol Eberl, Matthias ; Cardiff University Fischbach, Michel; CHU hautepierre, Fraser, Donald; Institute of Nephrology, Jörres, Achim; Universitätsklinikum Charite, Dept. Nephrology and Medical Intensive Care ; University Witten/Herdecke, Medical Center Cologne-Merheim, Department of Medicine I - Nephrology, Transplantation & Medical Intensive Care Kratochwill, Klaus; zytoprotec GmbH Lopéz-Cabrera, Manuel; Centro de Biología Molecular Severo Ochoa, CSIC-UAM Rutherford, Peter; Glyndwr University Schmitt, claus; Center for Pediatrics and Adolescent Medicine, Division of Pediatric Nephrology Nocolas, Topley; Institute of Nephrology, University of Wales College of Medicine, Heath Park, Cardiff, UK. Witowski, Janusz; University Medical School, Pathophysiology</p>
Keywords:	peritoneal dialysis, peritoneal membrane, fibrosis, inflammation, peritonitis
Subject Area:	Dialysis

SCHOLARONE™
Manuscripts

Biomarker Research to Improve Clinical Outcomes in Peritoneal Dialysis

– Consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) Network

Christoph Aufricht MD¹, Robert Beelen PhD², Matthias Eberl PhD³, Michel Fischbach MD⁴, Donald Fraser PhD³, Achim Jörres MD^{5,6}, Klaus Kratochwill PhD^{7,8}, Manuel LópezCabrera PhD⁹, Peter Rutherford PhD^{10,#}, Claus-Peter Schmitt MD¹¹, Nicholas Topley PhD³, Janusz Witowski MD¹²

¹ Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria; ² VU Medisch Centrum, Amsterdam, NL; ³ Cardiff University, Cardiff, UK; ⁴ Université de Strasbourg, Strasbourg, France; ⁵ Department of Nephrology and Medical Intensive Care, Charité University Hospital Campus Virchow-Klinikum, Berlin, Germany; ⁶ Department of Medicine I - Nephrology, Transplantation & Medical Intensive Care, University Witten/Herdecke, Medical Center Cologne-Merheim, Cologne, Germany; ⁷ Zytotec, Vienna, Austria; ⁸ Christian Doppler Laboratory for Molecular Stress Research in Peritoneal Dialysis, Medical University of Vienna, Vienna, Austria; ⁹ Centro de Biología Molecular Severo Ochoa - Consejo Superior de Investigaciones Científicas, Madrid, Spain; ¹⁰ Glyndŵr University, Wrexham, UK; ¹¹ Universitätsklinikum Heidelberg, Heidelberg, Germany; ¹² Department of Pathophysiology, Poznan University of Medical Science, Poznan, Poland

PR was employed by Baxter Healthcare during the consensus process.

Corresponding author:

Professor Achim Jörres; Department of Medicine I - Nephrology, Transplantation & Medical Intensive Care, University Witten/Herdecke, Medical Center Cologne-Merheim, Ostmerheimer Str. 2000, D-51109 Cologne, Germany; E-mail: JoerresA@kliniken-koeln.de

Running head: Biomarkers in PD effluent

Abstract

Peritoneal dialysis therapy (PD) has a substantial need for biomarker as tools to identify patients that are at highest risk for PD-related complications and to guide personalised interventions that may improve clinical outcome in the individual patient. In this consensus paper, members of the European Training and Research in Peritoneal Dialysis Network (EuTRiPD) review the current status of biomarker research in PD and suggest a selection of biomarkers that might become relevant for the care of PD patients and which is directly accessible in PD effluents.

Currently used biomarkers collected in a Delphi procedure were first triaged for inclusion as surrogate endpoints for a clinical trial (IL-6, IL-8, *ex-vivo* stimulated IL-6 release, CA-125, AOPP). Next, novel biomarkers were selected as promising candidates for proof-of-concept studies, and differentiated into inflammation-signature (including IL-17, M₁/M₂, T_{reg}/Th17), MMT-signature (including miR-21, miR-31) as well as signatures for senescence and inadequate cellular stress responses. Finally, the need to define pathogen-specific immune fingerprints and phenotype associated molecular signatures (PAMS) utilizing effluents from clinical cohorts of PD patients, and 'omics technologies and bioinformatics/biostatistics was expressed as need for future joint research efforts.

Biomarker research in PD offers the potential to develop valuable tools to improve patient management. However, for all biomarkers discussed in this consensus paper, **the association of biological rationales to relevant clinical outcomes remains to be rigorously validated in adequately powered, prospective independent clinical studies.**

Keywords: renal replacement therapy, surrogate markers, peritonitis, epithelial–mesenchymal transition, ultrafiltration failure, proteomics

Background

Peritoneal dialysis (PD) is an effective, home-based form of renal replacement therapy that promotes patient autonomy. A significant proportion of patients who initiate PD suffer from PD-related clinical complications that may limit duration of treatment, including peritonitis and peritoneal membrane damage.¹ PD patients are also at high risk of other serious and life threatening illnesses, most notably cardiovascular diseases. Current approaches to patient monitoring, however, are mostly limited to approximating delivered dose of dialysis and measurements of membrane transport status. Consequently, despite considerable improvements in patient management and overall technique survival, there is a substantial unmet medical need for biomarkers as tools to identify patients that are at the highest risk and to guide personalised interventions in order to improve clinical outcome of PD in the individual patient.

In the clinical context, a biomarker is a proxy of disease mechanisms, which gives relevant information for decision-making regarding the diagnosis and/or therapy of a patient. Another classical definition is: "A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological response to a therapeutic intervention".² This information may become directly obvious from the molecular processes that reflect disease status, such as increased levels of inflammatory mediators in biological fluids due to increased production and release from inflamed tissues or local leukocytes. However, biomarker levels may also reflect mere changes of distribution between compartments, such as leakage from intracellular into extracellular, or spill over from systemic into local compartments by altered clearance.³ Accordingly, identification and interpretation of appropriate biomarkers is not trivial, and the clinical value of attractive biomarker candidates is difficult to predict and requires careful preclinical and clinical validation.⁴

This consensus paper focuses on those biomarkers that are thought to be relevant for the care of PD patients, but are limited to the "local" peritoneal level, *i.e.*, biomarkers that are directly

1
2
3 accessible in PD effluents. In what clinical circumstances would these biomarkers be of
4
5 benefit? Used as a risk-assessment tool (see figure 1), prognostic peritoneal biomarkers might
6
7 help to identify patients that are at highest risk for PD-related complications. For example,
8
9 biomarkers that reflect chronicity of peritoneal inflammatory processes might identify patients
10
11 prone to progressive loss of membrane function. Similar to sepsis research, biomarkers that
12
13 reflect depressed immuno-competence might identify increased infectious susceptibility in PD,
14
15 such as PD-related peritonitis. Monitoring a set of biomarkers that reflects the activity of
16
17 relevant pathomechanisms might thus help to guide therapeutic decisions or, following
18
19 therapeutic interventions, allow early discrimination between responder and non-responder
20
21 subgroups. Introduction of such predictive biomarkers (see figure 1) will likely facilitate the
22
23 implementation of stratified medicine into the clinical setting of PD. For example, a high pro-
24
25 inflammatory status in a given PD patient might necessitate the introduction of anti-
26
27 inflammatory local therapy by novel PD fluids. However, biomarkers predicting a particularly
28
29 high risk for PD-related complications might also allow a timely switch to alternate forms of
30
31 renal replacement in non-responding patients. Importantly, combinations of these biomarkers
32
33 may also be used as surrogate parameters for well-defined hard outcomes in the clinical
34
35 development for novel PD fluids. Such biomarkers are particularly relevant tools as the “hard
36
37 outcomes” require large studies with several hundred patients observed over several years
38
39 and thus present major logistic and economic obstacles for dearly needed early clinical trials in
40
41 PD.¹ Finally, biomarkers might also be implemented as a diagnostic tool. For example, a
42
43 certain pattern of cytokines might reflect the nature of the causative pathogen in peritoneal
44
45 infection and thus allow gaining quick and reliable diagnostic information relevant for
46
47 therapeutic decisions (e.g., the guidance of antibiotic regime).
48
49
50
51
52
53
54
55

56 FIGURE 1

57
58
59 TABLE 1
60

1
2
3 Several effluent biomarkers, such as CA-125 (believed to represent mesothelial cell mass) and
4
5 IL-6 (indicating local inflammation), have already been shown to be informative at the
6
7 population level in the follow-up of PD patients. However, at present the integration of effluent
8
9 biomarkers into clinical decision making in PD is only modest.⁵ In this consensus paper,
10
11 members of the European Training and Research in PD Network (EuTRiPD) discuss the
12
13 current status and prospect of a selection of novel effluent biomarkers.
14
15

16 17 18 19 **Hypothesis-Driven Peritoneal Biomarker Research**

20
21
22 The recent development of effluent biomarkers in PD has predominantly been hypothesis-
23
24 driven and based on pathologies and pathomechanisms found to be relevant for the course of
25
26 disease in PD. The biomarkers discussed in the following section are primarily related to
27
28 chronic inflammation, peritoneal membrane remodeling and peritoneal infection.
29
30

31 32 33 **Biomarker research in the context of Chronic Peritoneal Inflammation**

34
35
36 Although not yet used in clinical routine, markers of chronic inflammation should be predictive
37
38 of reduced survival in PD and HD patients, however, use of inflammatory cytokines and other
39
40 related molecules as biomarkers must take into account of the complexity of their function and
41
42 associations in this context. The most thoroughly studied marker of inflammation in PD
43
44 patients is Interleukin-6 (IL-6), which is also a major target for therapy in other diseases.⁶
45
46 Systemic levels of IL-6 and its soluble receptor are elevated in patients with end-stage renal
47
48 disease (ESRD), and circulating IL-6 levels at initiation of PD therapy predict the mortality
49
50 risk.⁷ Multiple factors may contribute to circulating IL-6 levels, including persistent or episodic
51
52 bouts of infection-inflammation, obesity, and metabolic alterations. Some of this excessive risk
53
54 also appears to be genetically controlled, with polymorphisms in the IL-6 gene being
55
56 associated with a high IL-6 producer status and reduced survival rates in patients undergoing
57
58 PD. Impaired clearance of IL-6 in patients with severely diminished kidney function may also
59
60 be contributing.

1
2
3 Cellular composition of the peritoneal effluent offers a unique view on the tissue-resident
4 immune system, and effluent cell and cytokine profiles reflect complex immunological
5 interactions active in the peritoneal membrane and cavity in response to chronic PD fluid
6 exposure and intercurrent infections. With regards to its role as a peritoneal biomarker, IL-6 is
7 increased in the effluent of patients suffering from acute bacterial peritonitis, where IL-6 is
8 required for effective bacterial clearance in the acute response to infection.⁸ Moreover,
9 elevated levels of pro-inflammatory cytokines might also be indicative of sub-clinical,
10 smoldering infections such as bacterial biofilms on PD catheters.⁹ Importantly, experimental
11 evidence in animal models links persistent peritoneal IL-6 generation to membrane
12 change/fibrosis¹⁰ and angiogenesis.¹¹ These processes may well bear clinical relevance as is
13 suggested by the results of the Global Fluid Study, a multinational, multicenter, prospective,
14 cohort study in 959 PD patients with up to 8 years of follow-up. Here it was found that local
15 peritoneal and systemic inflammation are uncoupled, and that local, not systemic,
16 inflammation is a main determinant of changes in peritoneal small solute transport rate that is
17 observed over time.¹²

18
19 Recently, T helper (Th)-17-mediated inflammatory response, and in particular the cytokine IL-
20 17, have been shown to play a central role in peritoneal damage.^{13,14} Experimental modulation
21 of the Th17 response and/or enhancing the regulatory T cell (Treg) response may preserve
22 membrane function.¹⁵⁻¹⁷ Thus, chronic inflammatory damage of the peritoneal membrane can
23 be modulated, at least in part, through regulation of the Th17/Treg balance.¹⁸ Other cytokines
24 are linked to specific PD-associated patient subgroups and characteristics. The chemokine
25 CCL18 (also known as PARC, DC-CK1 and MIP-4) had originally been described to be
26 predictive of encapsulating peritoneal sclerosis (EPS), but this finding was not confirmed by
27 recent studies.^{19,20} Peritoneal levels of CXCL8 (IL-8) were measured as part of the immune
28 fingerprinting during bacterial peritonitis²¹, yet increased secretion of IL-8 may also be a
29 feature of the senescence phenotype (see below). Thus, high readings of inflammatory
30 markers such as IL-6 or other cytokines are currently suggested as emerging biomarkers for

1
2
3 further clinical development (see table 1) but may require differential interpretations depending
4
5 on the clinical context.^{12,22-29}
6
7
8
9

10 Biomarker research in the context of Peritoneal Membrane Remodeling

11
12
13 Currently, data on peritoneal transport characteristics from the peritoneal equilibration test
14 (PET), and in particular their change over time, are used to guide PD patient treatment and
15 management. The previously well-discussed candidate biomarker CA-125 was rapidly applied
16 to estimate mesothelial cell mass as a surrogate parameter for the peritoneal membrane
17 status in studies comparing different dialysis fluids (see table 1), although its utility in this
18 context remains contentious.^{3,5,30}
19
20
21
22
23
24
25

26
27 Peritoneal mesothelial-to-mesenchymal transition (MMT) and inflammation establish a
28 feedback loop in which the MMT process may induce inflammatory mediators, which again
29 promote MMT.³¹ Moreover, fibroblast play a role in this process.³² As a result the peritoneal
30 membrane undergoes a progressive remodeling with the accumulation of extracellular matrix
31 and fibrosis. Peritoneal infections aggravate the peritoneal membrane remodeling process.
32
33 Patients who remain infection-free, however, also evidence PD induced inflammation and
34 fibrosis, which may result in loss of peritoneal membrane function and ultimately cessation of
35 PD.^{33,34} Assessment of the progressive morphological alterations would require repetitive
36 peritoneal biopsies, which is, however, feasible in clinical routine only at time of catheter
37 insertion and at time of subsequent abdominal surgery.³⁵ Alternatively, the *ex vivo* study of
38 effluent-derived mesothelial cells might be useful to monitor peritoneal remodeling.³⁶ Effluent
39 mesothelial cells show a progressive loss of epithelial phenotype and acquire fibroblastic
40 characteristics through MMT.³⁷⁻³⁹ MMT is a complex process during which mesothelial cells
41 are transformed into fibroblast-like cells with the capacity of producing a wide spectrum of
42 inflammation, fibrosis and angiogenesis mediators.³³ The *ex vivo* expression of molecules
43 associated with MMT in effluent mesothelial cells is associated with peritoneal transport
44 status.^{40,41} Moreover, levels of MMT-associated molecules in the PD effluent, including VEGF,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 CTGF/CCN2 and Gremlin-1, were also found to correlate with peritoneal transport.⁴²⁻⁴⁴ The
4
5 next goal is to develop a combination of MMT-related molecules that can be measured in the
6
7 PD effluent at once (MMT-Chip) and offer diagnostic/prognostic value.
8
9

10 Another line of research is the identification of different peritoneal fibroblast phenotypes whose
11
12 features may serve as a fingerprint of changes in the peritoneal membrane during PD.
13
14 Activated fibroblasts (myofibroblasts) originate from several precursors, including mesothelial
15
16 cells, resident fibroblasts, endothelial cells, and circulating fibrocytes and contribute most to
17
18 tissue fibrosis.⁴⁵ Experiments using inducible genetic fate mapping indicated type I collagen-
19
20 producing submesothelial fibroblasts as specific progenitors of α -SMA-positive myofibroblasts
21
22 that accumulate progressively in animals exposed to sodium hypochlorite, hyperglycemic
23
24 dialysis solutions, or TGF- β 1, suggesting an alternative mechanism of peritoneal fibrosis to
25
26 MMT.⁴⁶ Moreover, fibroblasts expressing Thy-1 (CD90) appear to have an increased ability to
27
28 acquire a myofibroblastic phenotype.³² Thus, the proportion of Thy-1⁺ and Thy-1⁻ fibroblasts
29
30 residing in the peritoneum may potentially identify individuals who are more prone to
31
32 myofibroblast expansion following peritoneal injury.
33
34
35
36
37
38
39

40 Biomarker research in the context of Peritoneal Infection

41
42 Peritoneal infection remains one of the main culprits for technical failure and patient morbidity
43
44 in PD. Whilst white cell counts (WCC) and the proportion of granulocytes in the peritoneal
45
46 effluent are widely accepted as biomarkers for infection⁴⁷ less progress has been achieved in
47
48 identifying biomarkers that discriminate between infection and non-infectious inflammation.
49
50 Culture-based diagnosis of infection is slow and error-prone, with 20-25% of cultures
51
52 remaining negative despite distinct clinical and biochemical signs of bacterial infection.⁴⁸ Direct
53
54 identification of pathogens using state-of-the-art technologies such as PCR or mass
55
56 spectrometry with satisfactory sensitivity and specificity remains a challenge.⁴⁹ Culture-
57
58 negative episodes of peritonitis may include cases of sterile inflammation that may not require
59
60 antimicrobial therapy but are often masked by inappropriate sample processing or

1
2
3 culture/detection conditions, especially for fastidious organisms and viruses.⁵⁰ When accurate
4 microbiological diagnosis in patients presenting with acute symptoms is not possible,
5 peritonitis management is largely empirical, and treatment with broad spectrum antibiotics is
6 recommended. Basic biomarkers identify culture-negative episodes, with culture-positive
7 infections having greatly elevated WCC values and higher frequencies of granulocytes.²¹
8 Moreover, levels of peritoneal effluent cytokines are lower in culture-negative episodes, with
9 e.g., IL-1 β and IL-10 showing potential for a distinction from infectious peritonitis.
10
11

12
13
14
15
16
17
18
19 When infection is present, biomarkers that are specifically associated with different types of
20 pathogens, maybe useful to distinguish fungal, bacterial and viral infections and thus help
21 inform the choice of treatment. In the absence of clear diagnostic parameters, prophylactic
22 treatment of all peritonitis patients with antifungals has been recommended whenever a
23 course of antibiotics is administered.⁵¹ In the case of bacterial pathogens, early discrimination
24 between Gram-positive and Gram-negative species would greatly reduce prescription of broad
25 spectrum antibiotics, Gram stainings of patient samples are routinely performed but lack
26 sensitivity.⁵² The availability of pathogen-specific biomarker signatures, combined with the
27 early identification of antimicrobial resistance patterns at the point of care, would represent a
28 major breakthrough in the accurate diagnosis and targeted therapy of peritonitis.⁵³ For
29 instance, biomarkers of particular relevance for the prediction of Gram-negative infections may
30 include comparatively higher levels of the cytokines IL-1 β , IL-10 and tumor necrosis factor
31 (TNF)- α compared to Gram-positive infections, combined with larger numbers of infiltrating
32 neutrophils and elevated frequencies of peritoneal $\gamma\delta$ T cells.²¹
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 A biomarker predicting risk for infections might also help to guide clinical decisions to improve
51 outcome in PD patients with compromised immunocompetence who are particularly
52 susceptible for infectious complications.⁵⁴⁻⁵⁷ In critically ill patients depressed
53 lipopolysaccharide (LPS)-stimulated release of TNF- α from whole blood has successfully been
54 used to detect systemic immunosuppression and to monitor immunomodulatory therapies.⁵⁸⁻⁶⁰
55
56
57
58
59
60 In PD, several studies have shown that *ex-vivo* stimulation of peritoneal macrophages isolated
from PD effluents results in increased cytokine release compared to constitutive

1
2
3 expression.^{55,61-64} Typical stimuli of cytokine release from peritoneal leucocytes are LPS and
4
5 Pam3Cys as ligands of Toll-like receptors (TLRs); typical read-outs are TNF- α and IL-6 as
6
7 rapidly reacting cytokines of known clinical relevance. Such assays demonstrated an
8
9 improvement of peritoneal macrophage function in patients dialyzed with neutral pH solutions
10
11 compared to patients receiving conventional therapy.^{55,61-63} *Ex-vivo stimulated cytokine release*
12
13 *in peritoneal effluents is therefore suggested as promising biomarker (see table 1), however,*
14
15 *prospective studies in larger PD populations are dearly needed to validate these assays as*
16
17 *surrogate parameters of immune competence and clinical outcome.*

18
19
20
21 Finally, there is a need for biomarkers to reliably predict outcome of infectious complications of
22
23 PD, to identify patients at risk of downstream complications, recurrent/relapsing infections and
24
25 even death, where extended hospitalization may be appropriate and catheter removal be
26
27 recommended. Moreover, infectious peritonitis might trigger smoldering sterile inflammation, a
28
29 condition requiring timely diagnosis to interrupt the subsequent vicious cycle activating multiple
30
31 of deleterious peritoneal pathomechanisms.⁶⁵ Different levels of local and/or systemic
32
33 immunocompetence and types of pathogens carry individual risks and outcomes, and as such
34
35 early biomarker-based stratification of patients may ultimately determine improved clinical
36
37 outcomes from infection. In this context the identification of high white cell counts or elevated
38
39 levels of peritoneal V δ 2⁺ T cells as early predictors of subsequent technique failure are
40
41 promising developments.^{53,66}

42 43 44 45 46 47 48 Biomarker research in the context of further pathomechanisms relevant to PD

49
50
51 Cellular senescence is a complex biological program triggered by stimuli that can put the
52
53 integrity of the genome at risk.⁶⁷ It is characterized by irreversible growth arrest, distorted cell
54
55 morphology and altered cytokine secretion (including increased release of IL-6 and CXCL8).⁶⁸
56
57 Peritoneal mesothelial cells in mice exposed chronically to PD fluids exhibit a phenotype
58
59 resembling that of senescent cells,⁶⁹ Likewise, the *in vitro* exposure of human peritoneal
60
mesothelial cells to high concentrations of glucose results in accelerated development of the

1
2
3 senescent cell phenotype,⁷⁰ partly through increased oxidative stress.⁷¹ Consequently, the
4 appearance of senescent mesothelial cells in the peritoneum may be indicative of peritoneal
5 membrane deterioration. However, the clinical exploitation of this concept is hampered by the
6 absence of a universal senescence marker ⁷² and difficulties in detecting senescent
7 mesothelial cells *in vivo*. In this respect, it might be easier to detect senescence among
8 mesothelial cells shed to the peritoneal effluent.⁷³

9
10
11
12
13
14
15
16
17 As oxidative stress is among the leading causes of premature senescence, the expression of
18 oxidative stress biomarkers may be useful as surrogate indicators of peritoneal membrane
19 deterioration. Oxidative stress is typically defined as a disturbance in the pro-oxidant /
20 antioxidant balance in favor of the former.⁷⁴ Reliable markers of oxidative stress should
21 consistently increase or decrease during periods of oxidative stress but not be impacted by
22 other cellular processes.⁷⁵ However, the interpretation of changes in currently measured
23 biomarkers of oxidative stress is challenging, as increased cellular antioxidant levels may
24 either reflect an improved antioxidant status or a compensatory response to an oxidative
25 insult. While several biomarkers of oxidative stress have been tested in PD patients such as
26 advanced oxidized protein products (AOPP, see table 1) in peritoneal effluents⁷⁶⁻⁷⁸, the
27 comprehensive assessment of a broad panel, especially in the context of cellular senescence,
28 remains to be performed and validated in clinical outcome related research.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44 The combination of these pathomechanisms may result in abnormal cellular stress responses,
45 potentially hampering peritoneal repair and propagating chronic inflammation.^{79,80} In
46 experimental PD, cellular expression of the inducible 27 kDa and 70 kDa heat-shock proteins
47 (Hsp27, Hsp72) has been shown to be dampened by PD fluid toxicity and inflammation.^{80,81} In
48 effluent derived mesothelial cell cultures from PD patients, expression of Hsp27 and Hsp72
49 was demonstrated to be influenced by *in vivo* and *ex vivo* MMT processes.⁸² Investigating the
50 cellular stress responses at the proteome level (see also below) demonstrated an inadequate
51 mesothelial Hsp72 expression that could be restored by therapeutic interventions.⁸³ These
52 data suggest that the assessment of the adequacy of peritoneal cell stress responses might
53 yield promising biomarkers to guide novel therapeutic interventions. To this end, alanyl-

1
2
3 glutamine dipeptide is currently tested in clinical trials and has been shown to restore
4 adequate cellular stress responses (NCT01353638, EudraCT2013-000400-42).⁸⁴ This
5 compound has recently been shown to increase the attachment of *N*-acetylglucosamine to
6 proteins (*O*-GlcNAcylation) in mesothelial cells and improve the resistance against PD-fluid
7 toxicity.⁸⁵ Accordingly, the monitoring of *O*-GlcNAc levels in peritoneal cells might evolve as an
8 independent novel biomarker for the preservation of peritoneal health in PD.
9
10
11
12
13
14
15
16
17
18

19 A particularly interesting approach to establish and/or validate biomarkers is given in the
20 pediatric PD population. Chronic renal failure is rare in this age group but in the majority of
21 children based on congenital disorders that are mostly limited to the kidneys and the urinary
22 tract, *i.e.* ruling out associated tissue alterations linked to systemic inflammation and aging. In
23 a world-wide effort, the International Pediatric Peritoneal Biobank has already collected more
24 than 300 parietal peritoneal and 200 omental tissue specimen, which allow for a systematic
25 comparison of the peritoneal membrane whole genome and proteome expression pattern in
26 health, uremia, and PD. Reference values of the healthy peritoneal membrane ultrastructure
27 (0-60 years) reflect major age specific particularities and now provide a framework for future
28 histomorphometric analyses and peritoneal transport modeling approaches³⁵. Preliminary
29 transcriptomics and proteomics findings obtained from omental arterioles, *i.e.* of tissue
30 samples not directly exposed to PD fluid but giving insight into uremia and PD associated
31 pathomechanisms of cardiovascular disease, elucidate the fundamental role of inflammatory
32 pathways with distinct elements of the innate immune system being consistently upregulated
33 on RNA and protein level.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 FIGURE 2
56
57
58
59
60

Non-Hypothesis-Driven Peritoneal Biomarker Research (Open “Omics” Approach)

1
2
3 Biomarker research based on the alternative “open approach” is increasingly productive due to
4
5 the improved availability of well-curated biobanks holding material from clinical cohorts, and
6
7 due to increasing experience with the use of ‘omics technologies and
8
9 bioinformatics/biostatistics in the setting of PD.

10
11
12 So-called unbiased strategies for biomarker identification may overcome the limitations of
13
14 candidates based on current hypotheses and available literature. Focusing on “known”
15
16 pathomechanisms and measuring surrogates of these pathomechanisms are likely to produce
17
18 more of the same information, and may thus overlook stronger predictors of outcome of
19
20 disease and therapy.

21
22
23 ‘Omics techniques aim to assess all biological molecules of a defined category (proteins,
24
25 nucleic acids, lipids, carbohydrates) in a biological system at the same time, thereby producing
26
27 a snapshot of the investigated sample. The result obtained from omics techniques is therefore
28
29 a system-wide list of absolute or relative abundance values, where usually the number of
30
31 individual features (proteins, transcripts, metabolites etc.) by far exceeds the number of
32
33 samples measured. This undersampling leads to a number of challenges regarding the
34
35 statistical exploration of the data, including the necessity to account for multiple testing of
36
37 hypotheses.

38
39
40 Importantly, the coverage of all molecules of a given type allows building statistical models not
41
42 only relying on a single marker but on a collection of markers, best discriminating between
43
44 different clinical outcomes, a so-called molecular signature. As single biomarkers can hardly
45
46 reflect the biological complexity of underlying diseases, comorbidities, genetic background and
47
48 context-dependent biological responses, molecular signatures are usually able to outperform
49
50 individual surrogate markers and therefore may represent more relevant biomarkers.

51 52 53 54 55 56 Proteomics in the context of PD

57
58 In the field of PD only a limited number of ‘omics studies has been performed, mostly trying to
59
60 identify pathomechanisms *in vitro* or in animal models, or individual biomarkers in PD effluent.
Using *in vitro* models, proteomics identified a molecular signature of the stress response to

1
2
3 PD-fluid exposure based on 60 mesothelial cell proteins, which were then used for evaluation
4 of pharmacological interventions^{83,86}. In animal models, a proteomic signature of extracellular
5 matrix (ECM) proteins was employed to characterize the effect of specific gene deletion on
6 MMT mechanisms.⁸⁷ None of these approaches have yet been applied to clinical samples.

7
8 PD effluent represents a particularly attractive material for biomarker research as it contains a
9 rich pool of biomolecules that are indicative of the peritoneal transport status as well as of
10 peritoneal health, ongoing pathological processes and even the status of underlying disease
11 and comorbidities. However, only few studies previously have used proteomics to investigate
12 PD effluent,⁸⁸⁻⁹⁹ identifying a very limited portion of the peritoneal proteome. This is due to the
13 fact that high abundance proteins originating from plasma mask low abundance proteins like
14 cytokines and chemokines as well as proteins from cellular origin. When focusing on these low
15 abundance biomarker candidates, depletion strategies are needed such as affinity-
16 chromatographic separation or semi-specific precipitation of proteins. A particularly promising
17 approach is the application of bead-based depletion and enrichment techniques, such as the
18 combinatorial peptide ligand library (CPLL) beads, also called equalizer beads. In this case a
19 limited number of binding sites for all potential proteins is available on the surface of the
20 beads, so that highly abundant protein species are saturated and the excess is removed
21 during the washing steps, whereas low abundant proteins are relatively enriched and therefore
22 detectable by analytical techniques such as 2D gel electrophoresis and/or liquid
23 chromatography coupled mass spectrometry (LC-MS).¹⁰⁰

24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Transcriptomics in the context of PD

50
51 PD effluent also contains a significant amount of nucleic acids, where messenger-RNA
52 (mRNA) transcripts might represent information about the activation status of individual genes.
53
54 Whilst free-floating mRNA in PD effluent is difficult to use as a biomarker due to its limited
55 stability, more stable species such as microRNAs should be potentially detectable in PD
56 effluent and used as biomarkers. MicroRNAs are short RNAs that bind to specific protein-
57 coding messenger RNA targets and repress synthesis of their respective proteins. There are
58
59
60

1
2
3 more than 2000 microRNAs encoded in the human genome, each predicted to repress the
4
5 synthesis of many proteins. MicroRNAs thus act as a complex layer of repressive regulation
6
7 for protein synthesis, and are critical for normal development, physiological processes, and
8
9 pathological mechanisms. Changes in microRNA expression are strongly linked to
10
11 fibrogenesis in many contexts (reviewed in ¹⁰¹).¹⁰²⁻¹⁰⁴ In studies of their role in peritoneal
12
13 dialysis to date, miRs -15a, -17, -21, -30, -192 and -377 were associated with peritoneal
14
15 transport characteristics in a cohort of 110 PD patients (reviewed in ¹⁰⁵).^{97,106-108}
16
17
18
19
20

21 Metabolomics in the context of PD

22
23 PD effluent comprises of a significant amount of biological metabolites as well as small
24
25 molecules originating from the original PD fluid and potential derivatives, such as glucose
26
27 adducts or break-down products of polymer osmotic agents. This fact renders metabolomics a
28
29 particularly attractive technique for generating molecular signatures from PD effluent. Up to
30
31 now a limited number of studies has been carried out, mainly focusing on proof-of-feasibility.
32
33 One study employed gas-chromatography coupled to MS or direct injection MS for generation
34
35 of metabolomics profiles of PD effluent from patients who later developed EPS compared to
36
37 matched controls.¹⁰⁹ One of the challenges in metabolomics analysis is the high redundancy of
38
39 small molecule masses based only on their exact mass. Therefore in the second available
40
41 study, a high resolution accurate mass (HR/AM) approach was combined with comparison of
42
43 experimental and *in-silico* fragmentation of candidate molecules to increase the likelihood of
44
45 unambiguous identification of metabolites increasing in PD effluent during a controlled 4 h PET
46
47 dwell.¹¹⁰
48
49
50
51
52

53 Defining phenotype associated molecular signatures in PD

54
55 Currently only limited data from omics approaches using PD effluent as sample material is
56
57 available. In the future, it would be particularly important to use biobanks generated from well-
58
59 defined clinical cohorts in order to define molecular signatures reflecting the pro-inflammatory
60

1
2
3 phenotype and/or peritoneal membrane status as has been discussed above for the
4
5 hypothesis-driven approach (see also Figure 1).
6

7
8 The amount of data generated from 'omics techniques can be enormous. Adequate IT
9
10 infrastructure for storage and retrieval of the data as well as streamlined statistical methods
11
12 are therefore a pre-requisite. The statistical analysis approach can either be "supervised",
13
14 using perfectly described clinical cohorts, linking a clinical phenotype to a molecular signature,
15
16 or "unsupervised", where algorithms for clustering the data or reducing its dimensions are
17
18 employed to find subgroups of samples which then have to be interpreted on the basis of the
19
20 available clinical data. Hierarchical clustering methods with its diverse range of distance
21
22 measures influencing the character of the analysis, principal components analysis (PCA)
23
24 where the first component explains the most variability in the data on the basis of the original
25
26 variables (loadings) by an Eigen-vector projection of orthogonal dimensions are prominent
27
28 examples of the unsupervised statistical analysis approach. Regarding the supervised
29
30 approach, machine learning techniques, where a training set of samples is used to select,
31
32 weight and combine classifiers which are then applied to a cohort of unknown cases/samples,
33
34 might be of specific use in the future. However, until now the application of such high-end
35
36 statistical approaches is still rare in the field of biomarker research, and even more so in the
37
38 field of PD. Usually, standard test statistics are employed and at best, individual promising
39
40 candidate markers are combined using linear models, which in many cases leads to overfitting
41
42 of the training data, thereby limiting the clinical applicability later on.
43
44
45

46
47 The technical validation of molecular signatures with biomarker potential, if possible using
48
49 orthogonal analytical techniques, as well as the verification of the predictive power of signature
50
51 candidates in independent sample cohorts is crucial to ensure clinical value. Eventually, a
52
53 molecular signature that is translated into clinical use will likely have to be measured using
54
55 rapid and cost-efficient methods, such as clinical chemistry techniques or multiplex ELISA. For
56
57 some applications targeted LC-MS methods might be available as a clinical routine tool in the
58
59 near future, enabling clinical integration of molecular signatures.
60

FIGURE 3

Conclusion and Clinical Outlook

Biomarker research in PD offers the potential to develop valuable tools to monitor therapy and improve patient management. However, for all biomarkers discussed in this consensus paper the association of biological rationales to clinically relevant outcomes (= phenotypes) remain to be rigorously tested. Comparable to the development of a novel drug, once the biological relevance of a candidate biomarker is established in the experimental preclinical setting, a preliminary validation in retrospective testing of biomaterials from biobanks or in sporadic clinical studies is mandatory. Finally, well-designed clinical trials are required to prospectively test the proof of concept and confirm the usefulness of the candidate biomarker in independent cohorts.

Only the strict performance of such clinical development plans will allow to adequately assess test characteristics (sensitivity, specificity, negative and positive predictive values) for a given biomarker and/or a combination of biomarkers as a prerequisite for their implementation in clinical practice. All currently suggested surrogate parameters for clinical PD fluid development have to be validated by comparison to their “hard” clinical outcome in sufficiently large case-control cohort studies. For example, about 350 PD patients would be needed to be followed for up to 2 years in an observational cohort study to detect biomarker differences with an effect size of 0.3 (=30% of their standard deviations), based on previously reported incidence rates of PD-related complications.^{1,111} In such a trial, follow-up with repeated sample collection is needed until sufficient pre-defined complications (such as peritonitis, ultrafiltration failure or deterioration of peritoneal membrane transport characteristics) have occurred. Biomarkers would then be assessed in stored samples and compared between PD patients with complications (=cases) and PD-patients who did not develop complications over the same length of observation (=controls).¹¹²

1
2
3 These **validated** biomarkers will then form the accepted basis to define a population of high
4 risk for clinical complications, which might particularly benefit from well-defined alternate
5 therapies in the context of precision medicine. Ultimately, any biomarker research needs to
6 incorporate an analysis of user requirements at the earliest possible time point. Any
7 biomarker-based test will be measured by its ability to provide value for money, not only to
8 improve patient outcomes but also to save costs for healthcare systems and generate revenue
9 for industrial partners. Given the relatively small number of PD patients worldwide compared to
10 other patient cohorts those commercial restraints are particularly relevant.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1

Clinical Question	EMERGING BIOMARKER			CURRENT LEVEL OF EVIDENCE	
	Consensus Suggested Surrogate Biomarker*	Concept / Hypothesis	reflecting patho-mechanism	Observed Associations (with reference)	Score*
Membrane Failure?	IL-6, IL-8	Peritoneal levels of IL-6 and IL-8 depend on basal activity of peritoneal immune cells	Smoldering Inflammation	Basal levels of cytokines in PD effluents are significantly associated with changes on peritoneal membrane transport characteristics, basal cytokine levels show no consistent differences between patients treated with different glucose-based PD fluids but significantly increased in PD patients treated with icodextrin containing regimens. ^{12,21-29}	A
Membrane Failure?	CA-125	CA-125 is produced by mesothelial cells and predominantly actively released into the peritoneal cavity	Membrane Remodeling	Peritoneal levels of CA-125 significantly decrease during longterm PD, CA-125 levels are lower with glucose based acidic single-chamber PD fluids than with pH neutral multi-chamber PD fluids or with glucose sparing regimens including PD fluids with alternate osmotic agents. ^{3,5,30}	A
Membrane Failure?	Advanced oxidized protein products AOPP	AOPP reflect posttranslational modification of proteins in the peritoneal cavity reflecting local stress	Oxidative Stress	Peritoneal levels of AOPP increase over dwell time and are higher with glucose based acidic single-chamber PD fluid than with pH neutral multi-chamber PD fluid. Levels of AOPP are correlated with peritoneal membrane transport characteristics. ⁷⁶⁻⁷⁸	B
Peritonitis?	Ex-vivo stimulated cytokine release	Ex-vivo exposure of peritoneal immune cells to TLR ligands results in maximally stimulated cytokine release	Impaired Host Defense	Ex-vivo stimulation of peritoneal macrophages isolated from PD effluents results in lower cytokine release in patients dialyzed with glucose based acidic single-chamber PD fluid than with pH neutral multi-chamber PD fluid. ^{55,61-63}	B
* all published studies report discovery research data and are scored regarding their confirmation level: A : significant association in >3 independent studies with >100 PD patients; B : significant association in ≥3 independent studies; C : significant association in <3 independent studies					

Figure Legends

Figure 1: Prognostic biomarkers help to identify PD patients who are at high risk of complications (such as peritoneal membrane deterioration or peritonitis) and should receive counteracting interventions (such as novel PD fluids). Predictive biomarkers help to identify those PD patients that are most responsive (or unresponsive) to a given intervention.

Figure 2: Biomarker research defined by a “targeted approach” starts hypothesis-driven from selected candidates, reflecting cellular mechanisms of interest, in the experimental setting and is then translated into the clinical context. Based on current evidence, the consortium selected surrogate biomarkers (given in bold) as endpoints to be assessed in a phase II clinical trial of a novel PD additive (EudraCT2013-000400-42/AT). The “open omics approach” starts with bio-material from well-defined clinical cohorts without any prior selection (non-hypothesis-driven). Clinical phenotypes to be assessed with molecular signatures (PAMS) as biomarkers were divided into pro-inflammatory and peritoneal membrane damage associated phenotypes. The pro-inflammatory phenotype was further divided into acute peritonitis and post-peritonitis triggered chronic inflammation. The membrane damage phenotype was further divided into mesothelial-to-mesenchymal transdifferentiation (MMT) and changes in peritoneal membrane function determined by peritoneal equilibration testing. Ideally, the two approaches have to be applied iteratively and their results have to be integrated to foster successful biomarker research. The definition of biomarkers also reflects the currently available technologies in a given research field. Thus, the introduction of omics approaches and advanced statistical models to the field of PD is a quintessential prerequisite to describe and define future biomarkers in the open approach.

1
2
3 Figure 3: Non-hypothesis-driven biomarker research following an open omics approach is
4 particularly attractive using PD effluent (PDE) as source for sample material. The **cellular**
5 **fraction** suspended in PDE can be analyzed using transcriptomics (focusing on mRNA) and
6 proteomics techniques. For soluble substances in PDE (**dissolved fraction**), transcriptomics
7 might be particularly attractive for micro RNAs (miRNA). Proteomics techniques can be
8 applied but require prior removal of high abundance proteins and/or enrichment of low
9 abundant biomarkers, and metabolomics techniques can be employed to quantify both
10 endogenous metabolites and small molecules specific to PD fluid exposure. Identified
11 molecules from all omics levels can be used for generation of pathogen associated molecular
12 signatures (PAMS) using statistical modeling techniques.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Disclosure

Funding Sources:

The authors were part of the European Training and Research in Peritoneal Dialysis (EuTRiPD) program, a project funded by the European Union within the Marie Curie scheme (287813).

For Peer Review Only

References

1. Cho Y, Johnson DW, Craig JC, Strippoli GF, Badve SV, Wiggins KJ. Biocompatible dialysis fluids for peritoneal dialysis. *Cochrane Database Syst Rev.* 2014;3:CD007554.
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clinical pharmacology and therapeutics.* 2001;69(3):89-95.
3. Redahan L, Davenport A. Peritoneal dialysate effluent and serum CA125 concentrations in stable peritoneal dialysis patients. *J Nephrol.* 2016;29(3):427-434.
4. Pavlou MP, Diamandis EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. *Clin Chem.* 2013;59(1):147-157.
5. Lopes Barreto D, Krediet RT. Current Status and Practical Use of Effluent Biomarkers in Peritoneal Dialysis Patients. *Am J Kidney Dis.* 2013.
6. Jones SA, Fraser DJ, Fielding CA, Jones GW. Interleukin-6 in renal disease and therapy. *Nephrol Dial Transplant.* 2014.
7. Cho Y, Johnson DW, Vesey DA, et al. Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients. *Perit Dial Int.* 2015;35(1):35-42.
8. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. *Nature.* 1994;368(6469):339-342.
9. Pihl M, Davies JR, Johansson AC, Svensater G. Bacteria on catheters in patients undergoing peritoneal dialysis. *Perit Dial Int.* 2013;33(1):51-59.
10. Fielding CA, Jones GW, McLoughlin RM, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. *Immunity.* 2014;40(1):40-50.
11. Catar R, Witowski J, Zhu N, et al. IL-6 Trans-Signaling Links Inflammation with Angiogenesis in the Peritoneal Membrane. *J Am Soc Nephrol.* 2016.
12. Lambie M, Chess J, Donovan KL, et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. *J Am Soc Nephrol.* 2013;24(12):2071-2080.
13. Rodrigues-Diez R, Aroeira LS, Orejudo M, et al. IL-17A is a novel player in dialysis-induced peritoneal damage. *Kidney Int.* 2014;86(2):303-315.
14. Ferrantelli E, Liappas G, Keuning ED, et al. A Novel Mouse Model of Peritoneal Dialysis: Combination of Uraemia and Long-Term Exposure to PD Fluid. *BioMed research international.* 2015;2015:106902.
15. Gonzalez-Mateo GT, Fernandez-Millara V, Bellon T, et al. Paricalcitol Reduces Peritoneal Fibrosis in Mice through the Activation of Regulatory T Cells and Reduction in IL-17 Production. *PLoS One.* 2014;9(10):e108477.
16. Sandoval P, Loureiro J, Gonzalez-Mateo G, et al. PPAR-gamma agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. *Lab Invest.* 2010.
17. Liappas G, Gonzalez-Mateo GT, Sanchez-Diaz R, et al. Immune-Regulatory Molecule CD69 Controls Peritoneal Fibrosis. *J Am Soc Nephrol.* 2016.
18. Liappas G, Gonzalez-Mateo GT, Majano P, et al. T Helper 17/Regulatory T Cell Balance and Experimental Models of Peritoneal Dialysis-Induced Damage. *BioMed research international.* 2015;2015:416480.
19. Ahmad S, North BV, Qureshi A, et al. CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis. *Eur J Clin Invest.* 2010;40(12):1067-1073.
20. Goodlad C, Tam FW, Ahmad S, Bhangal G, North BV, Brown EA. Dialysate cytokine levels do not predict encapsulating peritoneal sclerosis. *Perit Dial Int.* 2014;34(6):594-604.
21. Lin CY, Roberts GW, Kift-Morgan A, Donovan KL, Topley N, Eberl M. Pathogen-specific local immune fingerprints diagnose bacterial infection in peritoneal dialysis patients. *J Am Soc Nephrol.* 2013;24(12):2002-2009.
22. le Poole CY, Welten AG, ter Wee PM, et al. A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation. *Perit Dial Int.* 2012;32(3):305-315.

23. Cho Y, Johnson DW, Vesey DA, et al. Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. *BMC Nephrol.* 2014;15(1):8.
24. Opatrna S, Lysak D, Trefil L, Parker C, Topley N. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions. *Perit Dial Int.* 2012;32(1):37-44.
25. Yung S, Lui SL, Ng CK, et al. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers. *Perit Dial Int.* 2015;35(2):147-158.
26. Yang X, Zhang H, Hang Y, et al. Intraperitoneal interleukin-6 levels predict peritoneal solute transport rate: a prospective cohort study. *Am J Nephrol.* 2014;39(6):459-465.
27. Cho JH, Hur IK, Kim CD, et al. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. *Nephrol Dial Transplant.* 2010;25(6):1964-1973.
28. Oh KH, Jung JY, Yoon MO, et al. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. *Nephrol Dial Transplant.* 2010;25(5):1639-1646.
29. Lai KN, Lam MF, Leung JC, et al. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. *Perit Dial Int.* 2012;32(3):280-291.
30. Barreto DL, Hoekstra T, Halbesma N, et al. The Association of Effluent CA125 with Peritoneal Dialysis Technique Failure. *Perit Dial Int.* 2015;35(7):683-690.
31. Lee YC, Hung SY, Liou HH, et al. Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells. *BioMed research international.* 2015;2015:595030.
32. Witowski J, Kawka E, Rudolf A, Jorres A. New Developments in Peritoneal Fibroblast Biology: Implications for Inflammation and Fibrosis in Peritoneal Dialysis. *BioMed research international.* 2015;2015:134708.
33. Aroeira LS, Aguilera A, Sanchez-Tomero JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. *J Am Soc Nephrol.* 2007;18(7):2004-2013.
34. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. *J Am Soc Nephrol.* 2010;21(7):1077-1085.
35. Schaefer B, Bartosova M, Macher-Goeppinger S, et al. Quantitative Histomorphometry of the Healthy Peritoneum. *Scientific reports.* 2016;6(in press):21344.
36. Lopez-Cabrera M, Aguilera A, Aroeira LS, et al. Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure. *Perit Dial Int.* 2006;26(1):26-34.
37. Yanez-Mo M, Lara-Pezzi E, Selgas R, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. *N Engl J Med.* 2003;348(5):403-413.
38. Aguilera A, Aroeira LS, Ramirez-Huesca M, et al. Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. *Int J Artif Organs.* 2005;28(2):164-169.
39. Jimenez-Heffernan JA, Aguilera A, Aroeira LS, et al. Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. *Virchows Archiv : an international journal of pathology.* 2004;444(3):247-256.
40. Aroeira LS, Lara-Pezzi E, Loureiro J, et al. Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. *J Am Soc Nephrol.* 2009;20(3):582-592.
41. Aroeira LS, Aguilera A, Selgas R, et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. *Am J Kidney Dis.* 2005;46(5):938-948.
42. Mizutani M, Ito Y, Mizuno M, et al. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. *Am J Physiol Renal Physiol.* 2010;298(3):F721-733.

- 1
2
3 43. Siddique I, Curran SP, Ghayur A, et al. Gremlin promotes peritoneal membrane injury
4 in an experimental mouse model and is associated with increased solute transport in
5 peritoneal dialysis patients. *Am J Pathol*. 2014;184(11):2976-2984.
- 6 44. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and
7 TGF-beta1 in peritoneal dialysis. *J Lab Clin Med*. 1999;134(2):124-132.
- 8 45. Liu Y, Dong Z, Liu H, Zhu J, Liu F, Chen G. Transition of mesothelial cell to fibroblast in
9 peritoneal dialysis: EMT, stem cell or bystander? *Perit Dial Int*. 2015;35(1):14-25.
- 10 46. **Chen YT, Chang YT, Pan SY, et al. Lineage Tracing Reveals Distinctive Fates for
11 Mesothelial Cells and Submesothelial Fibroblasts during Peritoneal Injury. *J Am Soc
12 Nephrol*. 2014; 25(12):2847-58..**
- 13 47. Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections
14 recommendations: 2010 update. *Perit Dial Int*. 2010;30(4):393-423.
- 15 48. Schaefer F, Borzych-Duzalka D, Azocar M, et al. Impact of global economic disparities
16 on practices and outcomes of chronic peritoneal dialysis in children: insights from the
17 International Pediatric Peritoneal Dialysis Network Registry. *Perit Dial Int*.
18 2012;32(4):399-409.
- 19 49. Fournier PE, Drancourt M, Colson P, Rolain JM, La Scola B, Raoult D. Modern clinical
20 microbiology: new challenges and solutions. *Nature reviews. Microbiology*.
21 2013;11(8):574-585.
- 22 50. Fahim M, Hawley CM, McDonald SP, et al. Culture-negative peritonitis in peritoneal
23 dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. *Am J
24 Kidney Dis*. 2010;55(4):690-697.
- 25 51. Campbell DJ, Johnson DW, Mudge DW, Gallagher MP, Craig JC. Prevention of
26 peritoneal dialysis-related infections. *Nephrol Dial Transplant*. 2015;30(9):1461-1472.
- 27 52. Bezerra DA, Silva MB, Caramori JS, et al. The diagnostic value of Gram stain for initial
28 identification of the etiologic agent of peritonitis in CAPD patients. *Perit Dial Int*.
29 1997;17(3):269-272.
- 30 53. Eberl M, Friberg IM, Liuzzi AR, Morgan MP, Topley N. Pathogen-Specific Immune
31 Fingerprints during Acute Infection: The Diagnostic Potential of Human gammadelta T-
32 Cells. *Frontiers in immunology*. 2014;5:572.
- 33 54. Lewis S, Holmes C. Host defense mechanisms in the peritoneal cavity of continuous
34 ambulatory peritoneal dialysis patients. 1. *Perit Dial Int*. 1991;11(1):14-21.
- 35 55. Mackenzie R, Holmes CJ, Jones S, Williams JD, Topley N. Clinical indices of in vivo
36 biocompatibility: the role of ex vivo cell function studies and effluent markers in
37 peritoneal dialysis patients. *Kidney Int Suppl*. 2003;64 (Suppl 88)(88):S84-93.
- 38 56. Brauner A, Hylander B, Jacobson SH, Moshfegh A, Lundahl J. Increased expression of
39 CD25 and HLA-DR on lymphocytes recruited into the peritoneal cavity in non-infected
40 CAPD patients. *Inflammation*. 2001;25(6):399-404.
- 41 57. de Lima SM, Otoni A, Sabino Ade P, et al. Inflammation, neoangiogenesis and fibrosis
42 in peritoneal dialysis. *Clin Chim Acta*. 2013;421:46-50.
- 43 58. Spittler A, Reissner CM, Oehler R, et al. Immunomodulatory effects of glycine on LPS-
44 treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression.
45 *FASEB J*. 1999;13(3):563-571.
- 46 59. Schildberger A, Rossmann E, Eichhorn T, Strassl K, Weber V. Monocytes, peripheral
47 blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns
48 following stimulation with lipopolysaccharide. *Mediators Inflamm*. 2013;2013:697972.
- 49 60. Ploder M, Pelinka L, Schmuckenschlager C, et al. Lipopolysaccharide-induced tumor
50 necrosis factor alpha production and not monocyte human leukocyte antigen-DR
51 expression is correlated with survival in septic trauma patients. *Shock*. 2006;25(2):129-
52 134.
- 53 61. Jones S, Holmes CJ, Mackenzie RK, et al. Continuous dialysis with
54 bicarbonate/lactate-buffered peritoneal dialysis fluids results in a long-term
55 improvement in ex vivo peritoneal macrophage function. *J Am Soc Nephrol*. 2002;13
56 Suppl 1:S97-103.
- 57
58
59
60

- 1
2
3 62. Mackenzie RK, Holmes CJ, Moseley A, et al. Bicarbonate/lactate- and bicarbonate-
4 buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha
5 secretion. *J Am Soc Nephrol*. 1998;9(8):1499-1506.
- 6 63. Mackenzie RK, Jones S, Moseley A, et al. In vivo exposure to bicarbonate/lactate- and
7 bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage
8 function. *Am J Kidney Dis*. 2000;35(1):112-121.
- 9 64. Liberek T, Lichodziejewska-Niemierko M, Knopinska-Posluszny W, et al. Generation of
10 TNFalpha and interleukin-6 by peritoneal macrophages after overnight dwells with
11 bicarbonate- or lactate-buffered dialysis fluid. *Perit Dial Int*. 2002;22(6):663-669.
- 12 65. van Diepen AT, van Esch S, Struijk DG, Krediet RT. The First Peritonitis Episode Alters
13 the Natural Course of Peritoneal Membrane Characteristics in Peritoneal Dialysis
14 Patients. *Perit Dial Int*. 2014.
- 15 66. Chow KM, Szeto CC, Cheung KK, et al. Predictive value of dialysate cell counts in
16 peritonitis complicating peritoneal dialysis. *Clin J Am Soc Nephrol*. 2006;1(4):768-773.
- 17 67. Campisi J. Aging, cellular senescence, and cancer. *Annu Rev Physiol*. 2013;75:685-
18 705.
- 19 68. Burton DG, Krizhanovsky V. Physiological and pathological consequences of cellular
20 senescence. *Cell Mol Life Sci*. 2014;71(22):4373-4386.
- 21 69. Gotloib L, Shostak A, Wajsbrodt V, Kushnier R. High glucose induces a hypertrophic,
22 senescent mesothelial cell phenotype after long in vivo exposure. *Nephron*.
23 1999;82(2):164-173.
- 24 70. Ksiazek K, Korybalska K, Jorres A, Witowski J. Accelerated senescence of human
25 peritoneal mesothelial cells exposed to high glucose: the role of TGF-beta1. *Lab*
26 *Invest*. 2007;87(4):345-356.
- 27 71. Ksiazek K, Breborowicz A, Jorres A, Witowski J. Oxidative stress contributes to
28 accelerated development of the senescent phenotype in human peritoneal mesothelial
29 cells exposed to high glucose. *Free Radic Biol Med*. 2007;42(5):636-641.
- 30 72. Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. *Nat*
31 *Rev Mol Cell Biol*. 2014;15(7):482-496.
- 32 73. Gotloib L, Gotloib LC, Khrizman V. The use of peritoneal mesothelium as a potential
33 source of adult stem cells. *Int J Artif Organs*. 2007;30(6):501-512.
- 34 74. Sies H, Cadenas E. Oxidative stress: damage to intact cells and organs. *Philosophical*
35 *transactions of the Royal Society of London. Series B, Biological sciences*.
36 1985;311(1152):617-631.
- 37 75. Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and
38 impact on muscle force production. *Physiological reviews*. 2008;88(4):1243-1276.
- 39 76. Zeier M, Schwenger V, Deppisch R, et al. Glucose degradation products in PD fluids:
40 do they disappear from the peritoneal cavity and enter the systemic circulation? *Kidney*
41 *Int*. 2003;63(1):298-305.
- 42 77. Latcha S, Hong S, Gibbons N, Kohn N, Mattana J. Relationship between dialysate
43 oxidized protein and peritoneal membrane transport properties in patients on peritoneal
44 dialysis. *Nephrol Dial Transplant*. 2008;23(10):3295-3301.
- 45 78. Ruiz M, Portero-Otín M, Pamplona R, et al. Chemical and immunological
46 characterization of oxidative nonenzymatic protein modifications in dialysis fluids. *Perit*
47 *Dial Int*. 2003;23(1):23-32.
- 48 79. Bender TO, Kratochwill K, Herzog R, et al. Injury-induced inflammation and inadequate
49 HSP expression in mesothelial cells upon repeat exposure to dual-chamber bag
50 peritoneal dialysis fluids. *Int J Artif Organs*. 2015;38(10):530-536.
- 51 80. Kratochwill K, Lechner M, Lichtenauer AM, et al. Interleukin-1 receptor-mediated
52 inflammation impairs the heat shock response of human mesothelial cells. *Am J*
53 *Pathol*. 2011;178(4):1544-1555.
- 54 81. Bender TO, Bohm M, Kratochwill K, et al. Peritoneal dialysis fluids can alter HSP
55 expression in human peritoneal mesothelial cells. *Nephrol Dial Transplant*.
56 2011;26(3):1046-1052.
- 57
58
59
60

- 1
2
3 82. Vargha R, Bender TO, Riesenhuber A, Endemann M, Kratochwill K, Aufricht C. Effects
4 of epithelial-to-mesenchymal transition on acute stress response in human peritoneal
5 mesothelial cells. *Nephrol Dial Transplant*. 2008;23(11):3494-3500.
6
7 83. Kratochwill K, Boehm M, Herzog R, et al. Alanyl-glutamine dipeptide restores the
8 cytoprotective stress proteome of mesothelial cells exposed to peritoneal dialysis
9 fluids. *Nephrol Dial Transplant*. 2012;27(3):937-946.
10
11 84. Kratochwill K, Boehm M, Herzog R, et al. Addition of Alanyl-Glutamine to Dialysis Fluid
12 Restores Peritoneal Cellular Stress Responses - A First-In-Man Trial. *PLoS One*.
13 2016;11(10):e0165045.
14
15 85. Herzog R, Bender TO, Vychytil A, Bialas K, Aufricht C, Kratochwill K. Dynamic O-linked
16 N-acetylglucosamine modification of proteins affects stress responses and survival of
17 mesothelial cells exposed to peritoneal dialysis fluids. *J Am Soc Nephrol*.
18 2014;25(12):2778-2788.
19
20 86. Kratochwill K, Lechner M, Siehs C, et al. Stress responses and conditioning effects in
21 mesothelial cells exposed to peritoneal dialysis fluid. *J Proteome Res*. 2009;8(4):1731-
22 1747.
23
24 87. Strippoli R, Loureiro J, Moreno V, et al. Caveolin-1 deficiency induces a MEK-ERK1/2-
25 Snail-1-dependent epithelial-mesenchymal transition and fibrosis during peritoneal
26 dialysis. *EMBO molecular medicine*. 2015;7(1):102-123.
27
28 88. Cuccurullo M, Evangelista C, Vilasi A, et al. Proteomic analysis of peritoneal fluid of
29 patients treated by peritoneal dialysis: effect of glucose concentration. *Nephrol Dial
30 Transplant*. 2011;26(6):1990-1999.
31
32 89. Oliveira E, Araujo JE, Gomez-Meire S, et al. Proteomics analysis of the peritoneal
33 dialysate effluent reveals the presence of calcium-regulation proteins and acute
34 inflammatory response. *Clinical proteomics*. 2014;11(1):17.
35
36 90. Bruschi M, Candiano G, Santucci L, et al. Proteomic profile of peritoneal effluents in
37 children on glucose- or icodextrin-based peritoneal dialysis. *Nephrol Dial Transplant*.
38 2011;26(1):308-316.
39
40 91. Bruschi M, Candiano G, Santucci L, et al. Combinatorial Peptide Ligand Library and
41 two dimensional electrophoresis: new frontiers in the study of peritoneal dialysis
42 effluent in pediatric patients. *J Proteomics*. 2015;116:68-80.
43
44 92. Wang HY, Tian YF, Chien CC, et al. Differential proteomic characterization between
45 normal peritoneal fluid and diabetic peritoneal dialysate. *Nephrol Dial Transplant*.
46 2010;25(6):1955-1963.
47
48 93. Wu HY, Liao AC, Huang CC, et al. Comparative proteomic analysis of peritoneal
49 dialysate from chronic glomerulonephritis patients. *BioMed research international*.
50 2013;2013:863860.
51
52 94. Tyan YC, Su SB, Ting SS, Wang HY, Liao PC. A comparative proteomics analysis of
53 peritoneal dialysate before and after the occurrence of peritonitis episode by mass
54 spectrometry. *Clin Chim Acta*. 2013;420:34-44.
55
56 95. Yang MH, Wang HY, Lu CY, et al. Proteomic profiling for peritoneal dialysate:
57 differential protein expression in diabetes mellitus. *BioMed research international*.
58 2013;2013:642964.
59
60 96. Wen Q, Zhang L, Mao HP, et al. Proteomic analysis in peritoneal dialysis patients with
different peritoneal transport characteristics. *Biochem Biophys Res Commun*.
2013;438(3):473-478.
97. Zhang L, Wen Q, Mao HP, et al. Developing a reproducible method for the high-
resolution separation of peritoneal dialysate proteins on 2-D gels. *Protein expression
and purification*. 2013;89(2):196-202.
98. Sritippayawan S, Chiangjong W, Semangoen T, et al. Proteomic analysis of peritoneal
dialysate fluid in patients with different types of peritoneal membranes. *J Proteome
Res*. 2007;6(11):4356-4362.
99. Araujo JE, Jorge S, Teixeira ECF, et al. A cost-effective method to get insight into the
peritoneal dialysate effluent proteome. *J Proteomics*. 2016.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
100. Lichtenauer AM, Herzog R, Tarantino S, Aufricht C, Kratochwill K. Equalizer technology followed by DIGE-based proteomics for detection of cellular proteins in artificial peritoneal dialysis effluents. *Electrophoresis*. 2014;35(10):1387-1394.
101. Bowen T, Jenkins RH, Fraser DJ. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. *J Pathol*. 2013;229(2):274-285.
102. Wilflingseder J, Reindl-Schwaighofer R, Sunzenauer J, et al. MicroRNAs in kidney transplantation. *Nephrol Dial Transplant*. 2014.
103. Lorenzen JM, Thum T. Circulating and urinary microRNAs in kidney disease. *Clin J Am Soc Nephrol*. 2012;7(9):1528-1533.
104. Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. *Nat Rev Nephrol*. 2011;7(5):286-294.
105. Lopez-Anton M, Bowen T, Jenkins RH. microRNA Regulation of Peritoneal Cavity Homeostasis in Peritoneal Dialysis. *BioMed research international*. 2015;2015:1-9.
106. Chen J, Kam-Tao P, Kwan BC, et al. Relation between microRNA expression in peritoneal dialysis effluent and peritoneal transport characteristics. *Dis Markers*. 2012;33(1):35-42.
107. Zhou Q, Yang M, Lan H, Yu X. miR-30a negatively regulates TGF-beta1-induced epithelial-mesenchymal transition and peritoneal fibrosis by targeting Snai1. *Am J Pathol*. 2013;183(3):808-819.
108. Zhang K, Zhang H, Zhou X, et al. miRNA589 regulates epithelial-mesenchymal transition in human peritoneal mesothelial cells. *J Biomed Biotechnol*. 2012;2012:673096.
109. Dunn WB, Summers A, Brown M, et al. Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis. *Nephrol Dial Transplant*. 2012;27(6):2502-2510.
110. Csaicsich D, Lichtenauer AM, Vychytil A, et al. Feasibility of Metabolomics Analysis of Dialysate Effluents from Patients Undergoing Peritoneal Equilibration Testing. *Perit Dial Int*. 2015;35(5):590-592.
111. Evans DW, Ryckelynck JP, Fabre E, Verger C. Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account. *Nephrol Dial Transplant*. 2010;25(7):2315-2322.
112. Nitsch D, Davenport A. Designing Epidemiology Studies to Determine the Incidence and Prevalence of Encapsulating Peritoneal Sclerosis (EPS). *Perit Dial Int*. 2015;35(7):678-682.




Figure 1: Prognostic biomarkers help to identify PD patients who are at high risk of complications (such as peritoneal membrane deterioration or peritonitis) and should receive counteracting interventions (such as novel PD fluids). Predictive biomarkers help to identify those PD patients that are most responsive (or unresponsive) to a given intervention.

248x185mm (300 x 300 DPI)

W Only




Figure 2: Biomarker research defined by a “targeted approach” starts hypothesis-driven from selected candidates, reflecting cellular mechanisms of interest, in the experimental setting and is then translated into the clinical context. Based on current evidence, the consortium selected surrogate biomarkers (given in bold) as endpoints to be assessed in a phase II clinical trial of a novel PD additive (EudraCT2013-000400-42/AT). The “open omics approach” starts with bio-material from well-defined clinical cohorts without any prior selection (non-hypothesis-driven). Clinical phenotypes to be assessed with molecular signatures (PAMS) as biomarkers were divided into pro-inflammatory and peritoneal membrane damage associated phenotypes. The pro-inflammatory phenotype was further divided into acute peritonitis and post-peritonitis triggered chronic inflammation. The membrane damage phenotype was further divided into mesothelial-to-mesenchymal transdifferentiation (MMT) and changes in peritoneal membrane function determined by peritoneal equilibration testing. Ideally, the two approaches have to be applied iteratively and their results have to be integrated to foster successful biomarker research. The definition of biomarkers also reflects the currently available technologies in a given research field. Thus, the introduction of omics approaches and advanced statistical models to the field of PD is a quintessential prerequisite to describe and define future biomarkers in the open approach.

237x131mm (300 x 300 DPI)

Only




Figure 3: Non-hypothesis-driven biomarker research following an open omics approach is particularly attractive using PD effluent (PDE) as source for sample material. The cellular fraction suspended in PDE can be analyzed using transcriptomics (focusing on mRNA) and proteomics techniques. For soluble substances in PDE (dissolved fraction), transcriptomics might be particularly attractive for micro RNAs (miRNA). Proteomics techniques can be applied but require prior removal of high abundance proteins and/or enrichment of low abundant biomarkers, and metabolomics techniques can be employed to quantify both endogenous metabolites and small molecules specific to PD fluid exposure. Identified molecules from all omics levels can be used for generation of pathogen associated molecular signatures (PAMS) using statistical modeling techniques.

232x144mm (300 x 300 DPI)